Potential Technology Application and Driving Factors: Pharmaceutical
TECHNOLOGY APPLICATION
AI for drug R&D
Vaccines that use engineered DNA to induce an immunologic response in the host against bacteria, parasites, viruses, and potentially cancer. Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) Vaccines
Immunotherapy- based drugs
Biosimilars
To create treatments that are applicable to groups of individuals or an individual unique patient who meet certain genetic characteristics. Genetic-based drugs (precision medicine)- personalisation
Drugs are made with high similarity to biologic drugs that have been approved to treat the same conditions and diseases as the original biologic. Biosimilar drugs must undergo rigorous clinical testing and government approval before they can be approved and prescribed to the general public. Malaysia has established a regulatory framework (Guidance Document and Guideline for Registration of Biosimilars in Malaysia, 2008) for the approval and use of biosimilars, ensuring safety, efficacy, and quality standards Digitalisation efforts in Malaysia have led to the widespread adoption of telemedicine and Advancement of biologics drugs in modern disease management remote monitoring solutions that create bigger market opportunity for the use of biosimilars in home- based care
To streamline R&D efforts, including calculating vast patient datasets into digestible, tangible information, identifying personalised / precision medicine opportunities or forecasting potential responses to new drugs.
Treatments that use certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways: stimulating or boosting the natural defences of your immune system so it works harder or smarter, to find and attack cancer cells. Rising exploration in immunotherapy-based drugs. The approach is increasingly being used for treatment of various cancers and companies are also exploring its use in the treatment for prevention of other chronic conditions like diabetes, cardiovascular diseases, Parkinson’s, and Multiple Sclerosis
DRIVING FACTORS
•
AI facilitated healthcare systems’ growth to enhance the efficacy of national and global healthcare systems and to democratise access to care AI wave of new R&D collaborations between key biopharma players and AI-driven companies, primarily start-ups
•
The Malaysian Genome Vaccine Institute championing the initiative to bring together researchers, geneticists, scientists, and medical specialists to brainstorm ways to make the Malaysian Genome project a success The Institute for Medical Research (IMR) of the National Institutes of Health (NIH), MOH is currently developing COVID-19 vaccines based on Inactivated Viruses and mRNA, representing the pinnacle of local vaccine research capabilities
•
•
The Precision Medicine Initiative for the nation by the Academy of Sciences Malaysia (ASM) and followed by a joint paper between ASM and the Ministry of Health on precision medicine, digital health and clinical trial hub National initiative to roll out a national genome sequencing initiative to test and profile patients with different diseases (cancers, diabetes, heart disease, rare diseases and also those with COVID-19 infections)
•
•
•
•
•
81
Malaysian Technology Strategic Outlook 2023/2024 Energy, Healthcare & Space Industry
Made with FlippingBook flipbook maker